ARTICLE | Company News
Escagenetics other research news
November 15, 1993 8:00 AM UTC
ESCAgenetics Corp. (ESN) ESN received a $50,000 Phase I SBIR from the National Cancer Institute to create taxoids that potentially will have higher efficacy than taxol and fewer side effects. ESN's ...